

# Elliot B Tapper

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2796572/publications.pdf>

Version: 2024-02-01

265  
papers

9,229  
citations

46918

47  
h-index

54797

84  
g-index

274  
all docs

274  
docs citations

274  
times ranked

9235  
citing authors

#	ARTICLE	IF	CITATIONS
1	Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2650-2666.	2.4	580
2	Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. <i>BMJ: British Medical Journal</i> , 2018, 362, k2817.	2.4	557
3	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
4	Use of Liver Imaging and Biopsy in Clinical Practice. <i>New England Journal of Medicine</i> , 2017, 377, 756-768.	13.9	280
5	Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021, 74, 1611-1644.	3.6	263
6	Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. <i>Gastroenterology</i> , 2019, 157, 1264-1278.e4.	0.6	252
7	Joint American Academy of Dermatology and National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1445-1486.	0.6	184
8	Rates of and Reasons for Hospital Readmissions in Patients With Cirrhosis: A Multistate Population-based Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1181-1188.e2.	2.4	166
9	A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation. <i>Hepatology</i> , 2019, 70, 1816-1829.	3.6	163
10	Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis. <i>Hepatology</i> , 2015, 62, 584-590.	3.6	156
11	The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. <i>Journal of Hepatology</i> , 2020, 73, 441-445.	1.8	155
12	The high burden of alcoholic cirrhosis in privately insured persons in the United States. <i>Hepatology</i> , 2018, 68, 872-882.	3.6	154
13	FibroScan (Vibration-Controlled Transient Elastography): Where Does It Stand in the United States Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 27-36.	2.4	133
14	Refining the Ammonia Hypothesis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 646-658.	1.4	127
15	A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 753-759.	2.4	124
16	Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 274-282.	8.2	124
17	The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 677-684.	0.2	122
18	The Incidence and Outcomes of Ischemic Hepatitis: A Systematic Review with Meta-analysis. <i>American Journal of Medicine</i> , 2015, 128, 1314-1321.	0.6	113

#	ARTICLE	IF	CITATIONS
19	Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2018, 154, 2111-2121.e8.	0.6	110
20	The Risks of Thromboembolism Vs. Recurrent Gastrointestinal Bleeding after Interruption of Systemic Anticoagulation in Hospitalized Inpatients With Gastrointestinal Bleeding: A Prospective Study. <i>American Journal of Gastroenterology</i> , 2015, 110, 328-335.	0.2	102
21	Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , 2021, 74, 474-482.	3.6	102
22	Review article: the diagnostic approach and current management of chylous ascites. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 816-824.	1.9	97
23	Projected increase in obesity and non-alcoholic steatohepatitis-related liver transplantation waitlist additions in the United States. <i>Hepatology</i> , 2019, 70, 487-495.	3.6	96
24	Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2019, 69, 1787-1797.	3.6	92
25	Levels of Alanine Aminotransferase Confound Use of Transient Elastography to Diagnose Fibrosis in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 932-937.e1.	2.4	89
26	Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study. <i>Lancet Public Health</i> , The, 2020, 5, e316-e323.	4.7	87
27	Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus. <i>American Journal of Gastroenterology</i> , 2020, 115, 989-1002.	0.2	87
28	Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in <i>Cd39/Entpd1</i> null Mice. <i>Hepatology</i> , 2013, 57, 205-216.	3.6	75
29	Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis. <i>JAMA Network Open</i> , 2020, 3, e2015626.	2.8	75
30	Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 734-743.	1.9	74
31	Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography. <i>American Journal of Gastroenterology</i> , 2015, 110, 1298-1304.	0.2	69
32	Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 22-27.	1.0	69
33	Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: A modeling study. <i>Hepatology</i> , 2022, 75, 1480-1490.	3.6	69
34	Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis. <i>Hepatology Communications</i> , 2019, 3, 1510-1519.	2.0	66
35	Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms. <i>American Journal of Gastroenterology</i> , 2020, 115, 1642-1649.	0.2	66
36	Patient-reported outcomes in cirrhosis: A scoping review of the literature. <i>Hepatology</i> , 2018, 67, 2375-2383.	3.6	62

#	ARTICLE	IF	CITATIONS
37	Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. <i>Hepatology</i> , 2016, 64, 1893-1899.	3.6	61
38	Virtual Consultations Through the Veterans Administration SCAN-ECHO Project Improves Survival for Veterans With Liver Disease. <i>Hepatology</i> , 2018, 68, 2317-2324.	3.6	61
39	Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. <i>Journal of Viral Hepatitis</i> , 2013, 20, 669-677.	1.0	60
40	A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis. <i>Hepatology</i> , 2018, 68, 1498-1507.	3.6	60
41	Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patient-Reported Outcomes in Cirrhosis. <i>Hepatology</i> , 2019, 69, 1676-1685.	3.6	55
42	Increased Morbidity and Mortality Associated with Falls Among Patients with Cirrhosis. <i>American Journal of Medicine</i> , 2018, 131, 645-650.e2.	0.6	53
43	Strategies to Reduce 30-Day Readmissions in Patients with Cirrhosis. <i>Current Gastroenterology Reports</i> , 2017, 19, 1.	1.1	52
44	Ethics Consultation at a Large Urban Public Teaching Hospital. <i>Mayo Clinic Proceedings</i> , 2010, 85, 433-438.	1.4	51
45	Building Effective Quality Improvement Programs for Liver Disease: A Systematic Review of Quality Improvement Initiatives. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1256-1265.e3.	2.4	51
46	Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: A prospective cohort study. <i>Hepatology</i> , 2016, 63, 1184-1189.	3.6	51
47	Psychoactive Medications Increase the Risk of Falls and Fall-related Injuries in Hospitalized Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1670-1675.	2.4	48
48	Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score. <i>PLoS ONE</i> , 2016, 11, e0147237.	1.1	48
49	Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. <i>Gastroenterology Report</i> , 2014, 2, 276-280.	0.6	46
50	Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests. <i>American Journal of Gastroenterology</i> , 2018, 113, 529-538.	0.2	45
51	Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index. <i>American Journal of Transplantation</i> , 2018, 18, 2566-2570.	2.6	45
52	Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1397-1405.	1.9	45
53	Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding. <i>American Journal of Medicine</i> , 2017, 130, 601.e1-601.e8.	0.6	44
54	Early Versus Delayed Colonoscopy in Hospitalized Patients With Lower Gastrointestinal Bleeding. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 352-359.	1.1	44

#	ARTICLE	IF	CITATIONS
55	Model for End-Stage Liver Disease–Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease. <i>Hepatology</i> , 2020, 72, 1747-1757.	3.6	42
56	Hospital volume and mortality after transjugular intrahepatic portosystemic shunt creation in the United States. <i>Hepatology</i> , 2018, 67, 690-699.	3.6	40
57	The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers. <i>Hepatology</i> , 2020, 71, 225-234.	3.6	40
58	Incidence and Bedside Predictors of the First Episode of Overt Hepatic Encephalopathy in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2020, 115, 2017-2025.	0.2	40
59	The clinical predictors of aetiology and complications among 173 patients presenting to the Emergency Department with oesophageal food bolus impaction from 2004–2014. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 91-98.	1.9	38
60	Body composition predicts mortality and decompensation in compensated cirrhosis patients: A prospective cohort study. <i>JHEP Reports</i> , 2020, 2, 100061.	2.6	38
61	Gamma-Glutamyl Transferase (GGT) – an old dog with new tricks?. <i>Liver International</i> , 2022, 42, 9-15.	1.9	38
62	Coagulopathy in cirrhosis – The role of the platelet in hemostasis. <i>Journal of Hepatology</i> , 2013, 59, 889-890.	1.8	37
63	Microbiome therapeutics for hepatic encephalopathy. <i>Journal of Hepatology</i> , 2021, 75, 1452-1464.	1.8	37
64	Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 540-548.	1.9	36
65	Rebleeding vs Thromboembolism After Hospitalization for Gastrointestinal Bleeding in Patients on Direct Oral Anticoagulants. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1893-1900.e2.	2.4	36
66	Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis. <i>Cancer</i> , 2016, 122, 852-858.	2.0	33
67	Interventions to improve physical function and prevent adverse events in cirrhosis. <i>Gastroenterology Report</i> , 2018, 6, 13-20.	0.6	33
68	The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study. <i>JHEP Reports</i> , 2019, 1, 154-161.	2.6	32
69	Acceptance and use of a smartphone application in cirrhosis. <i>Liver International</i> , 2020, 40, 1556-1563.	1.9	32
70	Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 1213-1220.	1.9	31
71	Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 204-215.e6.	2.4	31
72	Serum Ammonia is Associated With Transplant-free Survival in Hospitalized Patients With Acutely Decompensated Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 345-350.	1.1	30

#	ARTICLE	IF	CITATIONS
73	Bedside Measures of Frailty and Cognitive Function Correlate with Sarcopenia in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3652-3659.	1.1	30
74	Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 652-660.	1.9	30
75	Risk Factors for Adverse Outcomes in Patients Hospitalized With Lower Gastrointestinal Bleeding. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1021-1029.	1.4	29
76	Low Likelihood of Intracranial Hemorrhage in Patients With Cirrhosis and Altered Mental Status. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 165-169.	2.4	29
77	Predicting Overt Hepatic Encephalopathy for the Population With Cirrhosis. <i>Hepatology</i> , 2019, 70, 403-409.	3.6	29
78	Osteoporosis in primary biliary cholangitis. <i>World Journal of Gastroenterology</i> , 2018, 24, 3513-3520.	1.4	29
79	Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review. <i>American Journal of Medicine</i> , 2017, 130, 744.e1-744.e7.	0.6	28
80	Extensive testing or focused testing of patients with elevated liver enzymes. <i>Journal of Hepatology</i> , 2017, 66, 313-319.	1.8	28
81	Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2338-2350.	1.1	28
82	Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002–2018: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1539-1548.	1.1	26
83	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 75, 1289-1299.	3.6	26
84	Contemporary Assessment of Hepatic Fibrosis. <i>Clinics in Liver Disease</i> , 2015, 19, 123-134.	1.0	25
85	A Longitudinal Study of Adenoma Detection Rate in Gastroenterology Fellowship Training. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2831-2837.	1.1	25
86	Falls are common, morbid, and predictable in patients with cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 582-588.	1.8	25
87	Paraduodenal Pancreatitis: Clinical Performance of MR Imaging in Distinguishing from Carcinoma. <i>Radiology</i> , 2013, 269, 475-481.	3.6	24
88	Portopulmonary Hypertension: Imatinib as a Novel Treatment and the Emory Experience With this Condition. <i>Transplantation Proceedings</i> , 2009, 41, 1969-1971.	0.3	23
89	Consults for Conflict: The History of Ethics Consultation. <i>Baylor University Medical Center Proceedings</i> , 2013, 26, 417-422.	0.2	23
90	Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis. <i>Annals of Gastroenterology</i> , 2016, 29, 341-7.	0.4	23

#	ARTICLE	IF	CITATIONS
91	Challenge accepted: Confronting readmissions for our patients with cirrhosis. <i>Hepatology</i> , 2016, 64, 26-28.	3.6	23
92	Determinants and outcomes of adherence to recommendations from a multidisciplinary tumour conference for hepatocellular carcinoma. <i>Hpb</i> , 2014, 16, 1009-1015.	0.1	22
93	A Multicenter Study Into Causes of Severe Acute Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1201-1203.	2.4	22
94	Low LDL-C and High HDL-C Levels Are Associated with Elevated Serum Transaminases amongst Adults in the United States: A Cross-sectional Study. <i>PLoS ONE</i> , 2014, 9, e85366.	1.1	21
95	Low fasting triglyceride levels are associated with noninvasive markers of advanced liver fibrosis among adults in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 106-116.	1.9	21
96	Optimizing medication management for patients with cirrhosis: Evidence-based strategies and their outcomes. <i>Liver International</i> , 2018, 38, 1882-1890.	1.9	21
97	Nonhospice Palliative Care Within the Treatment of End-Stage Liver Disease. <i>Hepatology</i> , 2020, 71, 2149-2159.	3.6	21
98	Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis. <i>Hepatology</i> , 2021, 73, 2429-2440.	3.6	21
99	The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis. <i>Transplantation</i> , 2017, 101, 987-995.	0.5	20
100	Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1197-1206.e7.	2.4	20
101	Systematic review: development of a consensus code set to identify cirrhosis in electronic health records. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 645-657.	1.9	20
102	Review article: current and emerging therapies for the management of cirrhosis and its complications. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1099-1115.	1.9	20
103	Staging laparoscopy for proximal pancreatic cancer in a magnetic resonance imaging-driven practice: what's it worth?. <i>Hpb</i> , 2011, 13, 732-737.	0.1	19
104	Non-Operative Management of Right Posterior Sectoral Duct Injury Following Laparoscopic Cholecystectomy. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 1237-1242.	0.9	19
105	Contemporary Epidemiology of Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 244-253.	0.3	19
106	Identifying Patients With Hepatic Encephalopathy Using Administrative Data in the ICD-10 Era. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 604-606.e1.	2.4	19
107	Assessment of National Organ Donation Rates and Organ Procurement Organization Metrics. <i>JAMA Surgery</i> , 2021, 156, 173.	2.2	18
108	Opioid and benzodiazepine prescription among patients with cirrhosis compared to other forms of chronic disease. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000271.	1.1	18

#	ARTICLE	IF	CITATIONS
109	Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 76, 251-274.	3.6	18
110	A unique benign mucinous cystadenoma of the retroperitoneum: a case report and review of the literature. <i>Archives of Gynecology and Obstetrics</i> , 2010, 281, 167-169.	0.8	17
111	Estimated Association Between Organ Availability and Presumed Consent in Solid Organ Transplant. <i>JAMA Network Open</i> , 2019, 2, e1912431.	2.8	17
112	Protective effects of coffee consumption following liver transplantation for hepatocellular carcinoma in cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 779-788.	1.9	17
113	Neurocognitive and Muscular Capacities Are Associated with Frailty in Adults with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3734-3743.	1.1	17
114	Cognitive Function, Sarcopenia, and Inflammation Are Strongly Associated with Frailty: A Framingham Cohort Study. <i>American Journal of Medicine</i> , 2021, 134, 1530-1538.	0.6	17
115	Viscoelastic Testing Prior to Non-surgical Procedures Reduces Blood Product Use Without Increasing Bleeding Risk in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5290-5299.	1.1	17
116	The Overuse of Serum Ceruloplasmin Measurement. <i>American Journal of Medicine</i> , 2013, 126, 926.e1-926.e5.	0.6	16
117	The efficacy and safety profile of albumin administration for patients with cirrhosis at high risk of hepatorenal syndrome is dose dependent. <i>Gastroenterology Report</i> , 2015, 3, 216-221.	0.6	16
118	The impact of race and ethnicity on mortality and healthcare utilization in alcoholic hepatitis: a cross-sectional study. <i>BMC Gastroenterology</i> , 2016, 16, 129.	0.8	16
119	Coordination of Care Is Associated With Survival and Health Care Utilization in a Population-Based Study of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2340-2348.e3.	2.4	16
120	Automated Measurements of Muscle Mass Using Deep Learning Can Predict Clinical Outcomes in Patients With Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 1210-1216.	0.2	16
121	Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nationwide Cohort Study. <i>Hepatology</i> , 2021, 74, 2725-2734.	3.6	16
122	Vibration-controlled transient elastography. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 192-198.	1.0	15
123	Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort. <i>Liver International</i> , 2020, 40, 947-955.	1.9	15
124	Effective Mentorship as a Means to Recruit, Retain, and Promote Underrepresented Minorities in Academic Gastroenterology and Hepatology. <i>American Journal of Gastroenterology</i> , 2021, 116, 1110-1113.	0.2	15
125	Alcohol Policies and Alcohol-related Liver Disease Mortality. <i>Gastroenterology</i> , 2021, 161, 350-352.	0.6	15
126	Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends. <i>Clinical Therapeutics</i> , 2022, 44, e45-e57.	1.1	15



#	ARTICLE	IF	CITATIONS
127	Doctors on Display: The Evolution of Television's Doctors. Baylor University Medical Center Proceedings, 2010, 23, 393-399.	0.2	14
128	Does Karnofsky Performance Status of Patients With Cirrhosis on the Transplant Waitlist Meet the Eyeball Test?. Clinical Gastroenterology and Hepatology, 2016, 14, 1196-1198.	2.4	14
129	Comparison of Vascular Plugs and Pushable Coils for Variceal Embolization After TIPS. American Journal of Roentgenology, 2017, 208, 650-655.	1.0	14
130	Dos and Don'ts in the Management of Cirrhosis: A View from the 21st Century. American Journal of Gastroenterology, 2018, 113, 927-931.	0.2	14
131	Why Do Individuals with Cirrhosis Fall? A Mechanistic Model for Fall Assessment, Treatment, and Research. Digestive Diseases and Sciences, 2019, 64, 316-323.	1.1	14
132	Coffee Consumption Is Associated With Lower Liver Stiffness: A Nationally Representative Study. Clinical Gastroenterology and Hepatology, 2022, 20, 2032-2040.e6.	2.4	14
133	The Morbidity and Mortality Conference in Gastroenterology and Hepatology: An Important Cornerstone of Patient Safety and Optimal Care. Gastroenterology, 2016, 150, 19-23.	0.6	13
134	Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C. Transplantation, 2017, 101, 933-937.	0.5	13
135	Frailty and Outcomes After Liver Transplantation. Current Transplantation Reports, 2019, 6, 1-6.	0.9	13
136	#LiverTwitter: An Emerging Tool for Liver Education and Research. Hepatology Communications, 2020, 4, 1229-1233.	2.0	13
137	Women on the liver transplantation waitlist are at increased risk of hospitalization compared to men. World Journal of Gastroenterology, 2018, 25, 980-988.	1.4	13
138	An MRI-Driven Practice: a New Perspective on MRI for the Evaluation of Adenocarcinoma of the Head of the Pancreas. Journal of Gastrointestinal Surgery, 2010, 14, 1292-1297.	0.9	12
139	Preventing and Treating Acute Kidney Injury Among Hospitalized Patients with Cirrhosis and Ascites: A Narrative Review. American Journal of Medicine, 2016, 129, 461-467.	0.6	12
140	Understanding and Reducing Ceruloplasmin Overuse with a Decision Support Intervention for Liver Disease Evaluation. American Journal of Medicine, 2016, 129, 115.e17-115.e22.	0.6	12
141	A Multicenter Evaluation of Adherence to 4 Major Elements of the Baveno Guidelines and Outcomes for Patients With Acute Variceal Hemorrhage. Journal of Clinical Gastroenterology, 2018, 52, 172-177.	1.1	12
142	Optimizing the use of twitter for research dissemination: The "Three Facts and a Story" randomized-controlled trial. Journal of Hepatology, 2021, 75, 271-274.	1.8	12
143	Isotretinoin Laboratory Monitoring in Acne Treatment. JAMA Dermatology, 2022, 158, 942.	2.0	12
144	A Decision Support Tool to Reduce Overtesting for Ceruloplasmin and Improve Adherence With Clinical Guidelines. JAMA Internal Medicine, 2015, 175, 1561.	2.6	11

#	ARTICLE	IF	CITATIONS
145	The Changing Role of Sodium Management in Cirrhosis. Current Treatment Options in Gastroenterology, 2016, 14, 274-284.	0.3	11
146	Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2018, 52, 444-451.	1.1	11
147	Comprehensive Health-Related State Utilities in Contemporary Patients With Cirrhosis. Hepatology Communications, 2020, 4, 852-858.	2.0	11
148	How Do Patients With Cirrhosis and Their Caregivers Learn About and Manage Their Health? A Review and Qualitative Study. Hepatology Communications, 2021, 5, 168-176.	2.0	11
149	A Telemonitoring Intervention for Cirrhotic Ascites Management Is Cost-Saving. Digestive Diseases and Sciences, 2022, 67, 854-862.	1.1	11
150	The Future of Quality Improvement for Cirrhosis. Liver Transplantation, 2021, 27, 1479-1489.	1.3	11
151	An Electronic Decision Support Intervention Reduces Readmissions for Patients With Cirrhosis. American Journal of Gastroenterology, 2022, 117, 491-494.	0.2	11
152	Pickle Juice Intervention for Cirrhotic Cramps Reduction: The PICCLES Randomized Controlled Trial. American Journal of Gastroenterology, 2022, 117, 895-901.	0.2	11
153	Suboptimal Implementation of Evidence-based Therapy for Acute Variceal Hemorrhage: A Systematic Review of Observational Studies. Clinical Gastroenterology and Hepatology, 2017, 15, 1373-1381.e7.	2.4	10
154	Outcomes of Patients With Cirrhosis Undergoing Orthopedic Procedures. Journal of Clinical Gastroenterology, 2019, 53, e356-e361.	1.1	10
155	Animal Naming Test Is Associated With Poor Patient-Reported Outcomes and Frailty in People With and Without Cirrhosis: A Prospective Cohort Study. Clinical and Translational Gastroenterology, 2022, 13, e00447.	1.3	10
156	Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection. Journal of Viral Hepatitis, 2015, 22, 974-976.	1.0	9
157	High Glasgow Blatchford Score at admission is associated with recurrent bleeding after discharge for patients hospitalized with upper gastrointestinal bleeding. Endoscopy, 2015, 48, 9-15.	1.0	9
158	Factors That Affect Results of Psychometric Tests to Identify Patients With Minimal Hepatic Encephalopathy. Clinical Gastroenterology and Hepatology, 2018, 16, 1836-1838.	2.4	9
159	Deprescribing medications that may increase the risk of hepatic encephalopathy: A qualitative study of patients with cirrhosis and their doctors. United European Gastroenterology Journal, 2021, 9, 193-202.	1.6	9
160	Comparison of Seven Noninvasive Models for Predicting Decompensation and Hospitalization in Patients with Cirrhosis. Digestive Diseases and Sciences, 2021, 66, 4508-4517.	1.1	9
161	The need for antibiotic stewardship and treatment standardization in the care of cirrhotic patients with spontaneous bacterial peritonitis – a retrospective cohort study examining the effect of ceftriaxone dosing. F1000Research, 2014, 3, 57.	0.8	9
162	Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States. Journal of Hepatology, 2022, 77, 377-382.	1.8	9

#	ARTICLE	IF	CITATIONS
163	Secondary Kwashiorkor: A Rare Complication of Gastric Bypass Surgery. <i>American Journal of Medicine</i> , 2015, 128, e1-e2.	0.6	8
164	Primary biliary cholangitis: new treatments for an old disease. <i>Frontline Gastroenterology</i> , 2017, 8, 29-36.	0.9	8
165	Nonalcoholic fatty liver disease, metabolic syndrome, and the fight that will define clinical practice for a generation of hepatologists. <i>Hepatology</i> , 2018, 67, 1657-1659.	3.6	8
166	The Pharmacologic Management of Osteoporosis in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Densitometry</i> , 2020, 23, 223-236.	0.5	8
167	Low-Value Levels: Ammonia Testing Does Not Improve the Outcomes of Overt Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2020, 115, 685-686.	0.2	8
168	Sugar-sweetened Beverages Are Associated With Increased Liver Stiffness and Steatosis Among Apparently Healthy Adults in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 959-961.e1.	2.4	8
169	International Classification of Diseases Codes are Useful in Identifying Cirrhosis in Administrative Databases. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2107-2122.	1.1	8
170	Teaching Quality Improvement on the Wards: How We Do It. <i>MedEdPORTAL: the Journal of Teaching and Learning Resources</i> , 0, , .	0.5	8
171	Nonselective Beta-blockers in Portal Hypertension: Why, When, and How?. <i>Clinical Liver Disease</i> , 2022, 19, 118-123.	1.0	8
172	Low Yield and Utilization of Confirmatory Testing in a Cohort of Patients with Liver Disease Assessed for Alpha-1 Antitrypsin Deficiency. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1589-1594.	1.1	7
173	A Standardized Assessment of Functional Disability Predicts 1-year Mortality in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 75-79.	1.1	7
174	Constitutional Challenges to Liver Transplant Policy. <i>Transplantation</i> , 2019, 103, e378-e381.	0.5	7
175	A Prospective, Blinded Assessment of Ammonia Testing Demonstrates Low Utility Among Front-Line Clinicians. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e895-e896.	2.4	7
176	Inpatient Gastroenterology Consultation and Outcomes of Cirrhosis-Related Hospitalizations in Two Large National Cohorts. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2094-2104.	1.1	7
177	The emotional burden of caregiving for patients with cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 2827-2835.	2.0	7
178	The Use of Administrative Data to Investigate the Population Burden of Hepatic Encephalopathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3620.	1.0	6
179	Do Nutritional Interventions Improve the Outcomes of Patients with Cirrhosis and Ascites: a Systematic Review of Randomized Trials. <i>Current Hepatology Reports</i> , 2020, 19, 71-77.	0.4	6
180	The incidence and outcome of postoperative hepatic encephalopathy in patients with cirrhosis. <i>United European Gastroenterology Journal</i> , 2021, 9, 672-680.	1.6	6

#	ARTICLE	IF	CITATIONS
181	Strategies to Improve Video Visit Use in Persons With Liver Disease. <i>Gastroenterology</i> , 2021, 161, 1080-1084.e2.	0.6	6
182	Association of chronic liver disease with cognition and brain volumes in two randomized controlled trial populations. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120117.	0.3	6
183	Hepatocellular Carcinoma-Related Mortality in the USA, 1999â€“2018. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4100-4111.	1.1	6
184	Deprescribing zolpidem reduces falls and fractures in patients with cirrhosis. <i>JHEP Reports</i> , 2022, 4, 100478.	2.6	6
185	Evaluation of Hemostatic Factors in Patients Undergoing Major Hepatic Resection and Other Major Abdominal Surgeries. <i>American Surgeon</i> , 2011, 77, 1188-1193.	0.4	5
186	Factors Affecting Adherence to a Quality Improvement Checklist on an Inpatient Hepatology Service. <i>Baylor University Medical Center Proceedings</i> , 2014, 27, 100-102.	0.2	5
187	Who Orders a Head CT?. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 632-638.	1.1	5
188	Hospitalâ€“level balloon tamponade use is associated with increased mortality for all patients presenting with acute variceal haemorrhage. <i>Liver International</i> , 2018, 38, 477-483.	1.9	5
189	Design and rationale of a randomizedâ€“controlled trial of home-delivered meals for the management of symptomatic ascites: the SALTYFOOD trial. <i>Gastroenterology Report</i> , 2019, 7, 146-149.	0.6	5
190	Causes and Rates of 30-Day Readmissions After Transjugular Intrahepatic Portosystemic Shunts. <i>American Journal of Roentgenology</i> , 2020, 215, 235-241.	1.0	5
191	A 78-Year-Old Man with Acute Myeloid Leukemia (AML) and Acute Renal Failure. <i>American Journal of Case Reports</i> , 2014, 15, 364-367.	0.3	5
192	Rate of Successful Extubation in Mechanically Ventilated Patients with Cirrhosis and Hepatic Coma. <i>Digestive Diseases and Sciences</i> , 2022, , 1.	1.1	5
193	Contemporary management of pain in cirrhosis: Toward precision therapy for pain. <i>Hepatology</i> , 2023, 77, 290-304.	3.6	5
194	Current knowledge of antibiotic prophylaxis guidelines regarding GI open-access endoscopic procedures is inadequate. <i>Gastrointestinal Endoscopy</i> , 2015, 82, 268-275.e7.	0.5	4
195	Early readmissions after liver transplantation and the power of quality improvement. <i>Liver Transplantation</i> , 2016, 22, 717-719.	1.3	4
196	How to Succeed in Research During Fellowship: What the Trainee Needs To Do (and Needs From the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.6	4
197	Embracing early discharge in patients with lower gastrointestinal bleeding. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 620-621.	3.7	4
198	Is Exercise Beneficial and Safe in Patients with Cirrhosis and Portal Hypertension?. <i>Current Hepatology Reports</i> , 2018, 17, 175-183.	0.4	4

#	ARTICLE	IF	CITATIONS
199	Hepatic encephalopathy and traffic accidents: Vigilance is needed!. <i>Journal of Hepatology</i> , 2019, 70, 590-592.	1.8	4
200	How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?. <i>Annals of Internal Medicine</i> , 2019, 171, 199.	2.0	4
201	ERCP in Patients With Cirrhosis: “Risky Business” Or “Just Do it”? <i>American Journal of Gastroenterology</i> , 2019, 114, 19-20.	0.2	4
202	Medically tailored meals for the management of symptomatic ascites: the SALTYFOOD pilot randomized clinical trial. <i>Gastroenterology Report</i> , 2020, 8, 453-456.	0.6	4
203	Applying Administrative Data-Based Coding Algorithms for Frailty in Patients With Cirrhosis. <i>Liver Transplantation</i> , 2021, 27, 1401-1411.	1.3	4
204	Nonalcoholic Fatty Liver Disease Natural History: Role of Mathematical Modeling. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 280-282.	2.4	4
205	Clinical pearls regarding Prinzmetal's angina complicated by cardiac arrest “management during therapeutic hypothermia. <i>International Journal of Cardiology</i> , 2012, 159, 55-57.	0.8	3
206	Reply to: “Circulating platelet derived microparticles are not increased in patients with cirrhosis”. <i>Journal of Hepatology</i> , 2013, 59, 913.	1.8	3
207	Multicenter Study Assessing Physician Recommendations Regarding the Continuation of Aspirin and/or NSAIDs Prior to Gastrointestinal Endoscopy. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3234-3241.	1.1	3
208	Cost Saving or Cost Effective? Unanswered Questions in the Screening of Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2019, 3, 1293-1295.	2.0	3
209	Impact of Inpatient Attending Specialty and Gastroenterology Consultation on Quality of Care of Patients Hospitalized with Decompensated Cirrhosis. <i>American Journal of Medicine</i> , 2021, 134, 1270-1277.e2.	0.6	3
210	Prevalence of High Liver Stiffness and a Screening Strategy Using the SODA-B Score Among US Adults. <i>Hepatology Communications</i> , 2022, 6, 898-909.	2.0	3
211	Evaluation of hemostatic factors in patients undergoing major hepatic resection and other major abdominal surgeries. <i>American Surgeon</i> , 2011, 77, 1188-93.	0.4	3
212	Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5327-5335.	1.1	3
213	Symptomatic Bile Duct Hamartomas: Surgical Management in an MRI Driven Practice. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 1265-1270.	0.9	2
214	Rifaximin for the prevention of readmissions for patients with hepatic encephalopathy “the price is right. <i>Liver International</i> , 2016, 36, 1252-1254.	1.9	2
215	Chest Pain Suggestive of a Life-Threatening Condition: A Department of Medicine Morbidity and Mortality Conference. <i>Psychosomatics</i> , 2016, 57, 89-96.	2.5	2
216	Tackling 30-Day Readmissions in Patients with Cirrhosis. <i>Current Hepatology Reports</i> , 2018, 17, 8-14.	0.4	2

#	ARTICLE	IF	CITATIONS
217	Reducing the Burden of False-Positive Tests: It Is Time to Optimize Diagnostic Testing for Undifferentiated Conditions. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1143-1146.	1.4	2
218	Transforming Chief Residents into Chief Scholars. <i>Medical Science Educator</i> , 2019, 29, 1135-1139.	0.7	2
219	Driving in the dark: cirrhosis in young adults. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 189-190.	3.7	2
220	A Trial of Ornithine Phenylacetate and the Arc of Ammonia's History in the Management of Overt Hepatic Encephalopathy. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2493-2495.	2.4	2
221	Social Support Does Not Modify the Risk of Readmission for Patients with Decompensated Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1855-1861.	1.1	2
222	A Claims-Based Frailty Risk Score Is Associated With Hospitalization for Acute-on-Chronic Liver Failure: But Is It Frailty?. <i>Liver Transplantation</i> , 2021, 27, 9-11.	1.3	2
223	How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?. <i>Annals of Internal Medicine</i> , 2019, 171, 862.	2.0	2
224	Identifying Ascites in Patients with Cirrhosis Using Administrative Codes and Diuretic Use: A Multicenter Study. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4695-4701.	1.1	2
225	A Two-Step Algorithm for the Noninvasive Identification of Candidates for Nonalcoholic Steatohepatitis Clinical Trials: The APRI-FAST. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1652-1653.	2.4	2
226	The aspartate aminotransferase-to-platelet ratio and the evaluation of non-alcoholic fatty liver disease. <i>Gastroenterology Report</i> , 2014, 2, 326-327.	0.6	1
227	Predictors of Negative Intraoperative Findings at Emergent Laparotomy in Patients with Cirrhosis. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 1777-1783.	0.9	1
228	Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient. <i>Pharmaceuticals</i> , 2014, 7, 18-28.	1.7	1
229	Contemporary Perspectives on the Pathophysiology and Management of Hepatic Hydrothorax. <i>Current Hepatology Reports</i> , 2015, 14, 212-218.	0.4	1
230	Lactulose vs Polyethylene Glycol for Treatment of Hepatic Encephalopathy. <i>JAMA Internal Medicine</i> , 2015, 175, 867.	2.6	1
231	Role of Noninvasive Fibrosis Methods in Management of Chronic Hepatitis B Virus. <i>Current Hepatology Reports</i> , 2016, 15, 220-229.	0.4	1
232	Optimizing the Outcomes Associated With Spontaneous Bacterial Peritonitis. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 191-194.	1.1	1
233	Editorial: the impact of steatosis on liver stiffness quantification is minimal. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1416-1417.	1.9	1
234	Towards patient-centred and cost-effective care for patients with cirrhosis and ascites. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 75-76.	3.7	1

#	ARTICLE	IF	CITATIONS
235	Hepatic Encephalopathy: A Diagnosis for the Individual but an Experience for the Household. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00181.	1.3	1
236	We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can. <i>Pharmacoeconomics</i> , 2020, 38, 427-429.	1.7	1
237	Attacking Alcohol-Related Liver Disease by Taxing Alcohol Sales. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 51-53.	1.4	1
238	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2457-2458.	2.4	1
239	The Role of Advanced Practice Providers in the Care of Nonalcoholic Fatty Liver Disease. <i>Clinical Therapeutics</i> , 2021, 43, 518-523.	1.1	1
240	Severe Hepatic Steatosis by Controlled Attenuation Parameter Predicts Quality of Life Independent of Fibrosis. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	1
241	Nondirected Testing for Inpatients With Severe Liver Injury. <i>Journal of Hospital Medicine</i> , 2017, 12, 184-187.	0.7	1
242	Frailty and Sarcopenia in the Critically Ill Patient with Cirrhosis. , 2020, , 141-160.		1
243	Deciphering the Cirrhotic Patient's Present Status: The Overlap Between Physical Frailty, Disability, and Sarcopenia. , 2020, , 25-32.		1
244	Falls are common, morbid, and predictable among people with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e1101-e1102.	0.8	1
245	Response to Gupta et al. Regarding Non-operative Management of Right Posterior Sectoral Duct Injury. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 2125-2126.	0.9	0
246	Letter in Response to the Recently Published Review: Hyponatremia in Cirrhosis and End-Stage Liver Disease—Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan. <i>Digestive Diseases and Sciences</i> , 2013, 58, 889-890.	1.1	0
247	Letter: seasonality in eosinophilic oesophagitis and food bolus obstruction — what about recurrent episodes? — Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 937-937.	1.9	0
248	Giant Cystic Arteriovenous Malformation of the Mesentery and the Role of Cross-Sectional Imaging in Occult Gastrointestinal Bleeding. <i>ACG Case Reports Journal</i> , 2015, 2, 158-160.	0.2	0
249	The Reply. <i>American Journal of Medicine</i> , 2016, 129, e263.	0.6	0
250	Letter: would aspirin alleviate fibrosis in alcoholic liver disease? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 209-210.	1.9	0
251	Reply to: "Should anti-LKM1 be routine for work-up of elevated liver enzymes?" <i>Journal of Hepatology</i> , 2017, 67, 418-419.	1.8	0
252	Reply. <i>Hepatology</i> , 2018, 67, 1637-1638.	3.6	0

#	ARTICLE	IF	CITATIONS
253	Reply. Hepatology, 2018, 67, 1636-1636.	3.6	0
254	Commentary. Clinical Chemistry, 2019, 65, 961-961.	1.5	0
255	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 1006.	2.4	0
256	Prescription opioid use is common and associated with worse clinical outcomes in individuals with chronic liver disease. GastroHep, 2020, 2, 13-21.	0.3	0
257	Letter: are opioid prescriptions associated with hepatic encephalopathy in patients with compensated cirrhosis? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 743-744.	1.9	0
258	Baffled by NAFLD: The Horse Might Be Out of the Barn but Should Not Take Us for a Ride. American Journal of Managed Care, 2021, 27, 364-365.	0.8	0
259	Reply to: "We need to talk about #livertwitter" Journal of Hepatology, 2021, 75, 1240-1241.	1.8	0
260	Finding Common Ground With Our MASQs Off. American Journal of Gastroenterology, 2021, 116, 837-837.	0.2	0
261	An Assessment of Ineligible Donor Use in Solid Organ Transplant. Transplantation, 2022, Publish Ahead of Print, .	0.5	0
262	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
263	OUP accepted manuscript. Gastroenterology Report, 2022, 10, goac015.	0.6	0
264	Falls are Common, Morbid, and Predictable among People with Cirrhosis.. European Journal of Gastroenterology and Hepatology, 2021, 33, e1101-e1102.	0.8	0
265	Pharmacist-led educational interventions involving the "hidden" patient in cirrhosis" Caregivers. Hepatology Communications, 2022, 6, 3283-3283.	2.0	0